Firstmark, a diagnostic division of GenWay Biotech, has presented the study results for preVent, a multiple biomarker test that diagnoses near term risk of myocardial infarction for suspected or confirmed coronary artery disease patients.
The PREvent blood test is based on technology developed and patented by GenWay, Emory University and MedStar.
Around 3,000 individuals with suspected or confirmed coronary artery disease were enrolled in Phase I and Phase II trials, in which PREvent identified the top 10% of confirmed coronary artery disease patients, who have a 6.45 times higher risk of a near-term myocardial infarction within a 2-3 year period.
In the study, the test also demonstrated to be 12 times effective than the single biomarker CRP.
GenWay Biotech president and CEO Thomas Silberg said the blood test will allow physicians to identify coronary artery disease patients that are in most urgent need of aggressive treatment and monitoring.